97 related articles for article (PubMed ID: 16339536)
1. The cytotoxicity receptor CRACC (CS-1) recruits EAT-2 and activates the PI3K and phospholipase Cgamma signaling pathways in human NK cells.
Tassi I; Colonna M
J Immunol; 2005 Dec; 175(12):7996-8002. PubMed ID: 16339536
[TBL] [Abstract][Full Text] [Related]
2. Many NK cell receptors activate ERK2 and JNK1 to trigger microtubule organizing center and granule polarization and cytotoxicity.
Chen X; Trivedi PP; Ge B; Krzewski K; Strominger JL
Proc Natl Acad Sci U S A; 2007 Apr; 104(15):6329-34. PubMed ID: 17395718
[TBL] [Abstract][Full Text] [Related]
3. Inhibition and activation by CD244 depends on CD2 and phospholipase C-gamma1.
Clarkson NG; Brown MH
J Biol Chem; 2009 Sep; 284(37):24725-34. PubMed ID: 19586919
[TBL] [Abstract][Full Text] [Related]
4. Influence of CRACC, a SLAM family receptor coupled to the adaptor EAT-2, on natural killer cell function.
Cruz-Munoz ME; Dong Z; Shi X; Zhang S; Veillette A
Nat Immunol; 2009 Mar; 10(3):297-305. PubMed ID: 19151721
[TBL] [Abstract][Full Text] [Related]
5. Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells.
Guo H; Cruz-Munoz ME; Wu N; Robbins M; Veillette A
Mol Cell Biol; 2015 Jan; 35(1):41-51. PubMed ID: 25312647
[TBL] [Abstract][Full Text] [Related]
6. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin.
Chen J; Zhong MC; Guo H; Davidson D; Mishel S; Lu Y; Rhee I; Pérez-Quintero LA; Zhang S; Cruz-Munoz ME; Wu N; Vinh DC; Sinha M; Calderon V; Lowell CA; Danska JS; Veillette A
Nature; 2017 Apr; 544(7651):493-497. PubMed ID: 28424516
[TBL] [Abstract][Full Text] [Related]
7. EAT-2, a SAP-like adaptor, controls NK cell activation through phospholipase Cγ, Ca++, and Erk, leading to granule polarization.
Pérez-Quintero LA; Roncagalli R; Guo H; Latour S; Davidson D; Veillette A
J Exp Med; 2014 Apr; 211(4):727-42. PubMed ID: 24687958
[TBL] [Abstract][Full Text] [Related]
8. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.
Collins SM; Bakan CE; Swartzel GD; Hofmeister CC; Efebera YA; Kwon H; Starling GC; Ciarlariello D; Bhaskar S; Briercheck EL; Hughes T; Yu J; Rice A; Benson DM
Cancer Immunol Immunother; 2013 Dec; 62(12):1841-9. PubMed ID: 24162108
[TBL] [Abstract][Full Text] [Related]
9. Fine specificity and molecular competition in SLAM family receptor signalling.
Wilson TJ; Garner LI; Metcalfe C; King E; Margraf S; Brown MH
PLoS One; 2014; 9(3):e92184. PubMed ID: 24642916
[TBL] [Abstract][Full Text] [Related]
10. Systemic lupus erythematosus immune complexes increase the expression of SLAM family members CD319 (CRACC) and CD229 (LY-9) on plasmacytoid dendritic cells and CD319 on CD56(dim) NK cells.
Hagberg N; Theorell J; Schlums H; Eloranta ML; Bryceson YT; Rönnblom L
J Immunol; 2013 Sep; 191(6):2989-98. PubMed ID: 23956418
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
van Rhee F; Szmania SM; Dillon M; van Abbema AM; Li X; Stone MK; Garg TK; Shi J; Moreno-Bost AM; Yun R; Balasa B; Ganguly B; Chao D; Rice AG; Zhan F; Shaughnessy JD; Barlogie B; Yaccoby S; Afar DE
Mol Cancer Ther; 2009 Sep; 8(9):2616-24. PubMed ID: 19723891
[TBL] [Abstract][Full Text] [Related]
12. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.
Hsi ED; Steinle R; Balasa B; Szmania S; Draksharapu A; Shum BP; Huseni M; Powers D; Nanisetti A; Zhang Y; Rice AG; van Abbema A; Wong M; Liu G; Zhan F; Dillon M; Chen S; Rhodes S; Fuh F; Tsurushita N; Kumar S; Vexler V; Shaughnessy JD; Barlogie B; van Rhee F; Hussein M; Afar DE; Williams MB
Clin Cancer Res; 2008 May; 14(9):2775-84. PubMed ID: 18451245
[TBL] [Abstract][Full Text] [Related]
13. CS1 Expression Pattern in NK Cells and Correlated Factors in Plasma Cell dyscrasias: Implications for Elotuzumab Therapy and CAR-T Efficacy.
Li C; Wang D; Xu Y; Mao X; Que Y; Li Z; Yu Q; Xu M; An N; Long X; Li C
J Cancer; 2024; 15(10):3065-3075. PubMed ID: 38706917
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Key Genes and miRNA-mRNA Networks Associated with Glucocorticoids Treatment in Chronic Obstructive Pulmonary Disease.
Wu JJ; Zhang PA; Chen MZ; Zhang Y; Du WS; Li XN; Ji GC; Jiang LD; Jiao Y; Li X
Int J Chron Obstruct Pulmon Dis; 2024; 19():589-605. PubMed ID: 38435123
[TBL] [Abstract][Full Text] [Related]
15. Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment.
Suzuki K; Yano S
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173885
[TBL] [Abstract][Full Text] [Related]
16. Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse.
Bhatt P; Kloock C; Comenzo R
Curr Oncol; 2023 Feb; 30(2):2322-2347. PubMed ID: 36826140
[TBL] [Abstract][Full Text] [Related]
17. SLAMF7 regulates the inflammatory response in macrophages during polymicrobial sepsis.
Wu Y; Wang Q; Li M; Lao J; Tang H; Ming S; Wu M; Gong S; Li L; Liu L; Huang X
J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36749634
[TBL] [Abstract][Full Text] [Related]
18. Deglycosylation of SLAMF7 in breast cancers enhances phagocytosis.
Wang SH; Chou WC; Huang HC; Lee TA; Hsiao TC; Wang LH; Huang KB; Kuo CT; Chao CH; Chang SJ; Hsu JM; Weng J; Ren N; Li FA; Lai YJ; Zhou C; Hung MC; Li CW
Am J Cancer Res; 2022; 12(10):4721-4736. PubMed ID: 36381324
[TBL] [Abstract][Full Text] [Related]
19. Akt isoforms in the immune system.
Guerau-de-Arellano M; Piedra-Quintero ZL; Tsichlis PN
Front Immunol; 2022; 13():990874. PubMed ID: 36081513
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of combination treatment with elotuzumab and lenalidomide is dependent on crosstalk between natural killer cells, monocytes and myeloma cells.
Richardson K; Keam SP; Zhu JJ; Meyran D; D'Souza C; Macdonald S; Campbell K; Robbins M; Bezman NA; Todd K; Quach H; Ritchie DS; Harrison SJ; Prince HM; Trapani JA; Jenkins MR; Beavis PA; Darcy PK; Neeson PJ
Haematologica; 2023 Jan; 108(1):83-97. PubMed ID: 35770527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
